NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
18.03
+0.21 (1.18%)
Nov 4, 2024, 4:00 PM EST - Market closed
NAMS Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Revenue | 7.42 | 14.09 | 102.69 | - | - |
Revenue Growth (YoY) | -32.30% | -86.28% | - | - | - |
Gross Profit | 7.42 | 14.09 | 102.69 | - | - |
Selling, General & Admin | 50.64 | 37.63 | 19.51 | 6 | 1.38 |
Research & Development | 165.47 | 159.42 | 86.74 | 28.97 | 4.05 |
Operating Expenses | 216.11 | 197.06 | 106.25 | 34.98 | 5.43 |
Operating Income | -208.69 | -182.97 | -3.56 | -34.98 | -5.43 |
Interest Expense | - | - | -0.29 | -0.41 | -0.34 |
Interest & Investment Income | 13.68 | 11.28 | - | - | - |
Currency Exchange Gain (Loss) | -1.35 | 5.06 | -9.75 | 1.71 | 0.02 |
Other Non Operating Income (Expenses) | - | - | -8 | -7.22 | - |
EBT Excluding Unusual Items | -196.36 | -166.63 | -21.59 | -40.9 | -5.75 |
Other Unusual Items | -33.02 | -10.28 | -1.04 | -0.88 | - |
Pretax Income | -229.38 | -176.91 | -22.63 | -41.79 | -5.75 |
Income Tax Expense | 0.03 | 0.03 | - | - | - |
Net Income | -229.4 | -176.94 | -22.63 | -41.79 | -5.75 |
Net Income to Common | -229.4 | -176.94 | -22.63 | -41.79 | -5.75 |
Shares Outstanding (Basic) | 87 | 82 | 19 | 11 | 5 |
Shares Outstanding (Diluted) | 87 | 82 | 19 | 11 | 5 |
Shares Change (YoY) | 108.42% | 333.20% | 72.75% | 119.58% | - |
EPS (Basic) | -2.64 | -2.15 | -1.19 | -3.81 | -1.15 |
EPS (Diluted) | -2.64 | -2.15 | -1.19 | -3.81 | -1.15 |
Free Cash Flow | -189.24 | -141.24 | 10.44 | -29.54 | -5.98 |
Free Cash Flow Per Share | -2.17 | -1.72 | 0.55 | -2.69 | -1.20 |
Gross Margin | 100.00% | 100.00% | 100.00% | - | - |
Operating Margin | -2811.00% | -1298.56% | -3.46% | - | - |
Profit Margin | -3090.01% | -1255.76% | -22.04% | - | - |
Free Cash Flow Margin | -2548.99% | -1002.43% | 10.17% | - | - |
EBITDA | -208.63 | -182.92 | -3.55 | -34.97 | -5.43 |
EBITDA Margin | - | - | -3.45% | - | - |
D&A For EBITDA | 0.06 | 0.05 | 0.01 | 0.01 | 0 |
EBIT | -208.69 | -182.97 | -3.56 | -34.98 | -5.43 |
EBIT Margin | - | - | -3.46% | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.